Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Biology

Cancer Oncology

Medicine

Internal Medicine

Hematology

Show all topics

DOI

10.1016/s0140-6736(19)31240-1

License

publisher-specific-oa